Evidence map›Paper›PMID 30862120›Full record

ArticleInternational journal of molecular sciences2019

Cytarabine-Resistant

Ya-Chen Ko, Chung-Yi Hu, Zheng-Hau Liu, Hwei-Fang Tien, Da-Liang Ou, Hsiung-Fei Chien, Liang-In Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia.Dose-response : a publication of International Hormesis Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ya-Chen KoDepartment of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu 300, Taiwan. koyc@mail.ypu.edu.tw.
Chung-Yi HuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 100, Taiwan. jcyhu@ntu.edu.tw.
Zheng-Hau LiuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 100, Taiwan. B99404035@ntu.edu.tw.
Hwei-Fang TienInternal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan. hftien@ntu.edu.tw.
Da-Liang OuDepartment of Oncology, College of Medicine, National Taiwan University, Taipei 100, Taiwan. dlou@ntu.edu.tw.
Hsiung-Fei ChienDivision of Plastic Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei 110, Taiwan. hfchien@h.tmu.edu.tw.
Liang-In LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 100, Taiwan. lilin@ntu.edu.tw.
National Taiwan University · TWNational Taiwan University Hospital · TWTaipei Medical University Hospital · TWYuanpei University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Internal tandem duplication of FLT3 juxtamembrane domain (FLT3-ITD)-positive acute myeloid leukemia (AML) leads to poor clinical outcomes after chemotherapy. We aimed to establish a cytarabine-resistant line from

Indexed as

Gene DeletionMutationTandem Repeat SequencesAnilidesApoptosis Regulatory ProteinsBiomarkersCell Line, TumorCell SurvivalCytarabineDNA Mutational AnalysisDose-Response Relationship, DrugDrug Resistance, Neoplasmfms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteMetabolic Networks and PathwaysAnilidesApoptosis Regulatory ProteinsBiomarkerscabozantinibCytarabineFLT3 protein, humanfms-Like Tyrosine Kinase 3PyridinesTP53 protein, humanTumor Suppressor Protein p53acute myeloid leukemiaCytarabinedrug-resistanceFLT3-ITD

Identifiers

PMID30862120
PMCPMC6429333
OpenAlexW2920911352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.